Abstract: Disclosed herein are salt and solvate forms of (4S,7aR,9aR,10R,11E,14S,15R)-6?-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3?,4?,7a,8,9,9a,10,13,14,15-decahydro-2?H,3H,5H-spiro[1,19-etheno-16,16-cyclobuta[i][1,4]oxazepino[3,4-f][1,2,7]thiadlazacyclohexadecine-4,1 naphthalene]-16,16,18 (7H,17H)-trione (AMG 397): (AMG 397), such as crystalline salt and solvate forms thereof. Also disclosed are methods of making the salt and solvate forms, and methods of treating diseases and disorders with the salt and solvate forms.

Abstract: Disclosed herein are crystalline forms of (4S,7aR,9aR,10R,11E,14S,15R)-6?-chloro-10-methoxy-14,15-dimethyl-10-{[(9aR)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methyl}-3?,4?,7a,8,9,9a,10,13,14,15-decahydro-2?H,3H,5H-spiro[1,19-etheno-1616-cyclobuta[i] [1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-4,1?-naphthalene]-16,16,18(7H,17H)-trione (AMG 397): (AMG 397), hydrates, and solvates thereof. Also disclosed are methods of making the crystalline forms, and methods of treating diseases and disorders with the crystalline forms.

Abstract: The disclosure provides processes for preparing Compound A, Compound E, Compound I, salts thereof, and/or stereoisomers thereof, as described herein.

Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: An instrument for reading a lateral flow assay device by detecting color changes based on human perception includes an optics module having a camera, a signal processor, a storage memory and a comparator circuit. The storage memory has stored therein a dataset of sample readings of reference assay devices similar in structure and function to that of the lateral flow assay device. The sample readings are based on human visual perceptions of colorimetric changes in the detection zones of the reference assay devices. The comparator circuit compares the measured colorimetric data relating to the assay device read by the instrument with the stored database of sample readings based on human visual perceptions of the colorimetric changes of the reference assay devices, and generates a comparison signal which is provided to the signal processor. The signal processor generates a determination signal indicative of the presence, absence or quantity of an analyte.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Abstract: A method comprising: hydrogenating an indole propionamide compound of formula h with vitride, to form an aminopropyl indole compound of formula i wherein m, Ar, R1 and R2 are as defined herein. The compounds prepared by the method of the invention are useful as monoamine reuptake inhibitors useful for treatment of CNS indications.

Abstract: The present invention provides a process for preparing biaryl compounds comprising reacting an arylzinc reagent with an arylchloride in the presence of a nickel catalyst or a palladium catalyst. The present invention specifically provides a process for the preparation of 2-(4′-methylphenyl)benzonitrile comprising reacting a 4-methylphenylzinc reagent with 2-chlorobenzonitrile in the presence of a nickel catalyst or a palladium catalyst.

Abstract: 4-R.sup.4 -R.sup.5 -2-Saccharinylmethyl aryl carboxylates, useful in the treatment of degenerative diseases, are prepared by reacting a 4-R.sup.4 -R.sup.5 -2-halomethylsaccharin with an arylcarboxylic acid in the presence of an acid-acceptor.

Abstract: A compound having the formula: ##STR1## wherein Ar, R.sup.4 and R.sup.5 are defined herein have pharmaceutical utility as proteolytic enzyme inhibitors.